CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

CRISPR Therapeutics (CRSP ... respectively. The recent announcement of the COO's resignation was likely a contributing factor to the decline, adding uncertainty around the company's strategic ...

Raches was six and his sister Jalachari 11 when their father, Krishna M. Ella, decided to leave his job as a faculty member ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%.

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...